On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Buy One get One Free with International Stem Cell Corporation (ISCO)

The recent initiation report on International Stem Cell Corporation (OTCQB: ISCO) by Edison Investment Research looks at the company from a novel perspective. Although described as ‘an early-stage cell therapy company currently in Phase I/IIa clinical trials to treat Parkinson’s disease (PD)’, the company is much more. It has two wholly-owned subsidiaries that are currently generating revenue. “These commercial businesses,” reads Edison’s report, “provide a floor under ISCO’s current valuation, creating an essentially free option” on ISCO’s biotech business devoted to the treatment of Parkinson’s disease. In other words, the analysts at Edison are saying that prospective investors can pay for the two subsidiaries and get the biotech business free.

The two subsidiaries are Lifeline Skin Care (LSC) and Lifeline Cell Technology (LCT). Lifeline Skin Care (LSC) develops and manufactures a line of luxury skincare products. The company globally markets these products through dermatologists, plastic surgeons, medical clinics, resort spas, other specialized channels and its website. Its major distributors are Amazon (NASDAQ: AMZN) and Dermstore. The LSC product line includes cleansers, exfoliators and a range of specialized moisturizers and serums. LSC’s potential for growth is enormous. The global skincare market is estimated at over $100 million and is growing at a CAGR of 3.3 percent, and LSC is certainly realizing its potential. Its revenues in recent years exploded at four times the industry rates, which were roughly 17 percent from 2012-2015.

Lifeline Cell Technology (LCT) is ISCO’s biomedical business. LCT develops, curates and markets human stem cells. Over the period from 2012-2015, revenue from ISCO’s biomedical business grew at a CAGR of 19 percent, or nearly three times the industry rate. These two subsidiaries comprise ISCO’s cosmeceutical and biomedical business lines.

Together, LSC and LCT had revenues of $7.5 million for the fiscal year ended December 31, 2015, with LSC reporting $3.5 million and LCT reporting $4 million. Edison expects revenues at the skincare business (LSC) to grow by 37 percent over the next 10 years, reaching $4.8 million by 2025. The biomedical subsidiary (LCT) is expected to do much better, more than doubling in size to get to $10.5 million over the same period.

Students of Brealey and Myers will remember that ‘we can think of stock price as the capitalized value of average earnings under a no-growth policy, plus PVGO, the present value of growth opportunities’. Such an approach values the cosmeceutical and biomedical businesses at a risk-adjusted net present value of $26 million, or $9.30 per share. To arrive at net present value (NPV), future cash flows were discounted at 10%. The risk adjustment to the NPV was 90%.

ISCO’s biotech business, revolving around the treatment of Parkinson’s disease, is valued at $31 million, or $10.90 per share, and the NPV of future general and administrative expenses works out to -$30 million, which just about cancels that out. Edison is estimating the chance that biotech revenues will materialize at about 1 in 13, or 7.5 percent. Also, there’s no valuation placed on the rest of the biotech business. If you like bargains, this might be one.

For more information, visit www.internationalstemcell.com

Let us hear your thoughts: International Stem Cell Corp. Message Board

Archives

Select A Month
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered